![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Clinical and Experimental Therapeutics Program, University of Georgia College of Pharmacy (A.E., A.K.H., J.H.), Vascular Biology Center (A.E., A.T., M.P.A.), Departments of Surgery (A.R., E.R., B.W., M.P.A.) and Pharmacology and Toxicology (R.W.C.), Medical College of Georgia, Augusta, Georgia; and University of Tromsø Institute of Pharmacy, Tromsø, Norway (J.S.J., C.S.)
Diabetes is associated with increased risk for complications following coronary bypass grafting (CABG) surgery. Augmented superoxide 
production plays an important role in diabetic complications by causing vascular dysfunction. The potent vasoconstrictor endothelin-1 (ET-1) is also elevated in diabetes and following CABG; however, the effect of ET-1 on 
generation and/or vascular dysfunction in bypass conduits remain unknown. Accordingly, this study investigated basal and ET-1-stimulated production in bypass conduits and determined the effect of on conduit reactivity. Saphenous vein specimens were obtained from nondiabetic (n = 24) and diabetic (n = 24) patients undergoing CABG. Dihydroethidium staining and NAD(P)H oxidase activity assays (5380 ± 940 versus 16,362 ± 2550 relative light units/µg) demonstrated increased basal levels in the diabetes group (p < 0.05). Plasma ET-1 levels were associated with elevated basal levels, and treatment of conduits with exogenous ET-1 further increased production and augmented vasoconstriction. Furthermore, vascular relaxation was impaired in the diabetic group (75 versus 40%), which was restored by scavenger superoxide dismutase. These findings suggest that ET-1 causes bypass conduits dysfunction via stimulation of production in diabetes. Novel therapies that attenuate generation in bypass conduits may improve acute and late outcome of CABG in diabetic patients.
Address correspondence to: Dr. Adviye Ergul, Medical College of Georgia, Clinical Pharmacy CJ-1020, 1120 15th Street, Augusta, GA 30912. E-mail: aergul{at}mail.mcg.edu
This article has been cited by other articles:
|
|
 |
|
  M. Descorbeth and M. B. Anand-Srivastava High glucose increases the expression of Gq/11{alpha} and PLC-{beta} proteins and associated signaling in vascular smooth muscle cells Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2135 - H2142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Maier Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Diabetes: Vascular Implications Vascular and Endovascular Surgery, August 1, 2008; 42(4): 305 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sachidanandam, A. Harris, J. Hutchinson, and A. Ergul Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Experimental Biology and Medicine, June 1, 2006; 231(6): 1016 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. Obrosova, V. R. Drel, P. Pacher, O. Ilnytska, Z. Q. Wang, M. J. Stevens, and M. A. Yorek Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited Diabetes, December 1, 2005; 54(12): 3435 - 3441. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
